• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves New Drug For Migraine Sufferers
(CNN) — The US Food and Drug Administration on Monday announced the approval of a drug called ubrogepant for the acute treatment of migraine, which could be a new option for people who can’t take or don’t respond to migraine medications currently on the market. The drug will be sold under the name Ubrelvy by the pharmaceutical company Allergan. It is considered effective for migraine with or without aura, referring to the sensory or visual disturbances that occur among roughly a third of migraine sufferers. “Ubrelvy represents an important new option for the acute treatment of migraine in adults, as...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 24, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Syndicated CBSN Boston FDA Migraines Source Type: news

New Drug To Treat Migraines Shows Promise
(CNN) — A new drug to treat migraines has shown promise in a large-scale clinical trial, offering hope to people unable to use current treatment options. The drug, ubrogepant, showed greater rates of pain and symptom relief from migraine compared to a placebo, with more than 20% of participants given the drug reporting to be pain-free within two hours and more than 34% relieved of the most bothersome symptoms linked to migraine, which include light and noise sensitivity. This is compared to 14% and 27%, respectively, from the placebo. “Having ubrogepant as a potential new medication for the acute treatment of m...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 19, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Migraines Source Type: news